Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
BMC Neurology
|
February 10, 2012
Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation
Susanne Hartz, Denis Getsios, Sunning Tao, et al.
International Journal of Technology Assessment in Health Care
|
September 28, 2004
Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research
Denis Getsios, Ingrid Caro, Wissam El-Hadi, et al.
Pharmacoeconomics
|
April 21, 2010
Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation
Denis Getsios, Steve Blume, K Jack Ishak, et al.
Dementia and Geriatric Cognitive Disorders
|
July 30, 2002
Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands
J Jaime Caro, Maribel Salas, Alexandra Ward, et al.
Pharmacoeconomics
|
July 27, 2002
Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden
Frances B Garfield, Denis Getsios, J Jaime Caro, et al.
BMC Geriatrics
|
December 17, 2003
Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis
Jaime Caro, Denis Getsios, Kristen Migliaccio-Walle, et al.
Applied Health Economics and Health Policy
|
October 4, 2012
Inclusion of compliance and persistence in economic models: past, present and future
Ananth Kadambi, Robert J Leipold, Anuraag R Kansal, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
April 15, 2014
Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis
Thitima Kongnakorn, James A Sterchele, Christopher G Salvador, et al.
Clinical Therapeutics
|
April 28, 2004
Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder
Denis Getsios, J Jaime Caro, K Jack Ishak, et al.
The Pediatric Infectious Disease Journal
|
May 7, 2005
Pertussis immunization of adolescents in the United States: an economic evaluation
J Jaime Caro, Denis Getsios, Wissam El-Hadi, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
BMC Neurology
|
February 10, 2012
Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation
Susanne Hartz, Denis Getsios, Sunning Tao, et al.
International Journal of Technology Assessment in Health Care
|
September 28, 2004
Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research
Denis Getsios, Ingrid Caro, Wissam El-Hadi, et al.
Pharmacoeconomics
|
April 21, 2010
Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation
Denis Getsios, Steve Blume, K Jack Ishak, et al.
Dementia and Geriatric Cognitive Disorders
|
July 30, 2002
Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands
J Jaime Caro, Maribel Salas, Alexandra Ward, et al.
Pharmacoeconomics
|
July 27, 2002
Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden
Frances B Garfield, Denis Getsios, J Jaime Caro, et al.
BMC Geriatrics
|
December 17, 2003
Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis
Jaime Caro, Denis Getsios, Kristen Migliaccio-Walle, et al.
Applied Health Economics and Health Policy
|
October 4, 2012
Inclusion of compliance and persistence in economic models: past, present and future
Ananth Kadambi, Robert J Leipold, Anuraag R Kansal, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
April 15, 2014
Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis
Thitima Kongnakorn, James A Sterchele, Christopher G Salvador, et al.
Clinical Therapeutics
|
April 28, 2004
Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder
Denis Getsios, J Jaime Caro, K Jack Ishak, et al.
The Pediatric Infectious Disease Journal
|
May 7, 2005
Pertussis immunization of adolescents in the United States: an economic evaluation
J Jaime Caro, Denis Getsios, Wissam El-Hadi, et al.
Page
of 4